April 16, 2026 4:52pm

Another I wrote/told you so as I stipulated “Uncle algo and his electronic trading dwarfs” are eating into the sector upside

New highs, spirit some byes as I have also written, “C&GT equities are STILL under a microscope during these times re their fair value until it’s clear that there is an end of the Iranian conflict.”

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

Thursday’s RMi Pre-opening: None, my warning came in Wednesday’s closing bell

Wednesday’s RMi Closing Bell: Slipping and sliding, sector share pricing … https://www.regmedinvestors.com/articles/14384

 I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

What happened and some of the whys with the numbers behind

… it’s NOT always about BUYs/SELLs … it’s about knowing when and what!

 

Thursday: The Dow closed UP +115.00 points or +0.24%, the S&P closed UP +18.33 points or +0.26% while the Nasdaq closed UP +86.687 points or +0.36%

  • Theme of the session: optimism for a possible resolution to the Iran war

Wednesday (my) 40-company covered sector’s advance/decline line opened negative with 7 incliners, 31 decliners and 2 flats, ending with a negative close of 12 incliner, 26 decliners and 2 flats

  • Slipping and sliding from Wednesday

The CBOE Fear (VIX) index, Thursday closed at 17.81, after Wednesday’s 18.17, Tuesday’s 18.47, Monday’s 19.33, Friday’s 19.30 and last Thursday’s 19.57

Metrics: Thursday …

  • The RUT was up +0.17 points or +4.69%,
  • The XLV was down -1.16 points or -0.79%,
  • The NBI was down -42.64 points or -0.70%;
  • The XBI was down -1 points or -0.73%
  • The IWM was up +0.59 or +0.22%;
  • The IBB was down -1.87 points or -1.06%,
  • The VIX was down -0.36 points or -1.98% at to 17.81
  • The SPX was up +17.72 or +0.25% to 7040.67

 

Q2/26 – 1 holiday, 1 neutral, 3 negative and 6 positive closes

  • Q1 -March – 9 positive and 13 negative closes
  • February – 1 holiday, 8 negative and 11 positive sessions
  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

 

Thursday Closing UP (12 of 12) 

  • BioNTech (BNTX +$2.65 after Wednesday’s +$1.06 after Tuesday’s +$1.71 after Monday’s +$1.51),
  • AxoGen (AXGN +$2.61),
  • Compass Therapeutics (CMPX +$0.68 after Wednesday’s +$0.41),
  • Moderna (MRNA +$0.42 after Wednesday’s +$1.42 after Tuesday’s +$2.16 after Monday’s -$0.28)
  • Mesoblast (MESO +$0.34 after Wednesday’s +$1.14 after Tuesday’s -$0.09 after Monday’s -$0.30),
  • Cellectis SA (CLLS +$0.18 after Wednesday’s -$0.07 after Tuesday’s -$0.12),
  • Fate Therapeutics (FATE +$0.08 after Wednesday’s -$0.05),
  • Solid Biosciences (SLDB +$0.07),
  • Lenz Therapeutics (LENZ +$0.96 after Wednesday’s -$0.32),
  • Precigen (PGEN +$0.05 after Wednesday’s -$0.06 after Tuesday’s -$0.21),
  • Rocket Therapeutics (RCKT +$0.02),
  • Brainstorm Cell Therapeutics (BCLI +$0.0090 after Wednesday’s -$0.0590)

Flat (2)

  • Generation Bio (GBIO) – acquired
  • Harvard Apparatus TR (OTCQB: HRGN),

Thursday’s Closing DOWN (10 of 26): 

  • Alnylam Pharmaceuticals (ALNY -$13.26 after Wednesday’s -$6.02 after Tuesday’s +$6.41 after Monday’s +$10.89),
  • IQVA Holdings (IQV -$6.16 after Wednesday’s +$2.82 after Tuesday’s +$3.23 after Monday’s +$4.63),
  • Vertex (VRTX -$6.05 after Wednesday’s -$2.58 after Tuesday’s +$4.23 after Monday’s +$3.61),
  • Arrowhead Pharmaceuticals (ARWR -$2.97 after Wednesday’s +$4.26 after Tuesday’s +$2.90),
  • Vericel (VCEL -$1.60),
  • Ionis Therapeutics (IONS -$11.56),
  • CRISPR Therapeutics (CRSP -$1.04 after Wednesday’s -$0.10 after Tuesday’s +$2.03 after Monday’s +$3.78),
  • Intellia Therapeutics (NTLA -$0.78),
  • Supernus Therapeutics (SUPN -$0.72 after Wednesday’s -$0.17),
  • Ultragenyx Pharmaceuticals RARE -$0.66 after Wednesday’s +$0.61 after Tuesday’s +$0.94),

 

The Bottom Line: More of the … WHY and a lot of what ifs …

Indexes hit the brakes on Thursday, not necessarily a bad thing.

  • After the S&P and Nasdaq capped off a furious rally to hit closing highs on Wednesday

The S&P 500 and Nasdaq were moving in and out of positive territory throughout the afternoon.

Watching the Russell 2000 (RUT) …

  • The RUT is not far from a record.
  • The small-cap index was down 0.1% on Thursday, but briefly traded above its 2,718.77 closing high from Jan. 22.
  • The RUT tumbled into correction in the wake of the Iran war, since expectations for interest rate cuts and impacts of higher oil prices both hit firms that are more sensitive to economic conditions and borrowing rates.

Strong profit reports from several big U.S. companies helped support the market and offset a climb for oil prices.

  • The price for a barrel of Brent crude rose back above $99. Treasury yields edged higher in the bond market, while stock indexes rose in much of Europe and Japan. <AP>

For the week:

  • The S&P 500 is up 224.39 points, or 3.3%.
  • The Dow is up 662.15 points, or 1.4%.
  • The Nasdaq is up 1,199.81 points, or 5.2%.
  • The Russell 2000 is up 89.01 points, or 3.4%.

 

April 3rd Week:

  • 4/16 - Thursday closed negative with 12 incliners, 26 decliners and 2 flats
  • 4/15 – Wednesday closed positive with 26 incliners, 12 decliners and 2 flats
  • 4/14 - Tuesday closed positive with 32 incliners, 6 decliners and 2 flats
  • 4/13 - Monday closed positive with 33 incliners, 5 decliners and 2 flats

April – 2nd Week

  • 4/10 - Friday closed negative with 7 incliners, 30 decliners and 3 flats
  • 4/9 - Thursday closed positive with 24 incliners, 13 decliners and 3 flats
  • 4/8 – Wednesday closed positive with 27 incliners, 8 decliners and 5 flats
  • 4/7 – Tuesday closed negative with 15 incliners, 21 decliners and 4 flats
  • 4/6 - Monday closed positive with 20 incliners, 18 decliners and 2 flats

April – 1st week

  • 4/2 - Thursday closed neutral with 19 incliners, 19 decliners and 2 flats
  • 4/1 – Wednesday closed positive with 29 incliners, 8 decliners and 3 flats

 

Q1/26 Earnings Release Dates:

  • AxoGen (AXGN) – Tuesday, 4/28
  • Alnylam Pharmaceuticals (ALNY) -Thursday, 4/30
  • IQVIA Holdings (IQV) – Tuesday, 5/5

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there – closed end funds” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Thursday: BioNTech (BNTX), AxoGen (AXGN) and Compass Therapeutics (CMPX)
  • Wednesday: IQIA Holdings (IQV), Arrowhead Pharmaceuticals (ARWR) and Moderna (MRNA)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), IQIA Holdings (IQV) and Vertex (VRTX)
  • Monday: Alnylam Pharmaceuticals (ALNY), IQIA Holdings (IQV) and Vertex (VRTX)

The worst three (3) in the session: Losers’

  • Thursday: Alnylam Pharmaceuticals (ALNY), IQIA Holdings (IQV) and Vertex (VRTX)
  • Wednesday: Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and Sarepta Therapeutics (SRPT)
  • Tuesday: uniQure NV (QURE), Precigen (PGEN) and Solid Biosciences (SLDB)
  • Monday: Arrowhead Pharmaceuticals (ARWR), Supernus Therapeutics (SUPN) and Ionis Pharmaceuticals (IONS)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.